Leukocyte telomere length and mortality risk in patients with type 2 diabetes

Anna Rita Bonfigli, Liana Spazzafumo, Francesco Prattichizzo, Massimiliano Bonafè, Emanuela Mensà, Luigina Micolucci, Angelica Giuliani, Paolo Fabbietti, Roberto Testa, Massimo Boemi, Fabrizia Lattanzio, Fabiola Olivieri

Research output: Contribution to journalArticle

Abstract

Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤ 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up. In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.

Original languageEnglish
Pages (from-to)50835-50844
Number of pages10
JournalOncotarget
Volume7
Issue number32
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Telomere
Type 2 Diabetes Mellitus
Leukocytes
Mortality
Telomere Shortening
Confounding Factors (Epidemiology)
Real-Time Polymerase Chain Reaction
Creatinine
Regression Analysis
Demography
Genes

Keywords

  • Aging
  • Gerotarget
  • Mortality
  • Telomere shortening
  • Type 2 diabetes

ASJC Scopus subject areas

  • Oncology

Cite this

Leukocyte telomere length and mortality risk in patients with type 2 diabetes. / Bonfigli, Anna Rita; Spazzafumo, Liana; Prattichizzo, Francesco; Bonafè, Massimiliano; Mensà, Emanuela; Micolucci, Luigina; Giuliani, Angelica; Fabbietti, Paolo; Testa, Roberto; Boemi, Massimo; Lattanzio, Fabrizia; Olivieri, Fabiola.

In: Oncotarget, Vol. 7, No. 32, 01.08.2016, p. 50835-50844.

Research output: Contribution to journalArticle

Bonfigli, AR, Spazzafumo, L, Prattichizzo, F, Bonafè, M, Mensà, E, Micolucci, L, Giuliani, A, Fabbietti, P, Testa, R, Boemi, M, Lattanzio, F & Olivieri, F 2016, 'Leukocyte telomere length and mortality risk in patients with type 2 diabetes', Oncotarget, vol. 7, no. 32, pp. 50835-50844. https://doi.org/10.18632/oncotarget.10615
Bonfigli AR, Spazzafumo L, Prattichizzo F, Bonafè M, Mensà E, Micolucci L et al. Leukocyte telomere length and mortality risk in patients with type 2 diabetes. Oncotarget. 2016 Aug 1;7(32):50835-50844. https://doi.org/10.18632/oncotarget.10615
Bonfigli, Anna Rita ; Spazzafumo, Liana ; Prattichizzo, Francesco ; Bonafè, Massimiliano ; Mensà, Emanuela ; Micolucci, Luigina ; Giuliani, Angelica ; Fabbietti, Paolo ; Testa, Roberto ; Boemi, Massimo ; Lattanzio, Fabrizia ; Olivieri, Fabiola. / Leukocyte telomere length and mortality risk in patients with type 2 diabetes. In: Oncotarget. 2016 ; Vol. 7, No. 32. pp. 50835-50844.
@article{e5d909c4182748f2b89edffb3885b79e,
title = "Leukocyte telomere length and mortality risk in patients with type 2 diabetes",
abstract = "Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95{\%}CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤ 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up. In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.",
keywords = "Aging, Gerotarget, Mortality, Telomere shortening, Type 2 diabetes",
author = "Bonfigli, {Anna Rita} and Liana Spazzafumo and Francesco Prattichizzo and Massimiliano Bonaf{\`e} and Emanuela Mens{\`a} and Luigina Micolucci and Angelica Giuliani and Paolo Fabbietti and Roberto Testa and Massimo Boemi and Fabrizia Lattanzio and Fabiola Olivieri",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.10615",
language = "English",
volume = "7",
pages = "50835--50844",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "32",

}

TY - JOUR

T1 - Leukocyte telomere length and mortality risk in patients with type 2 diabetes

AU - Bonfigli, Anna Rita

AU - Spazzafumo, Liana

AU - Prattichizzo, Francesco

AU - Bonafè, Massimiliano

AU - Mensà, Emanuela

AU - Micolucci, Luigina

AU - Giuliani, Angelica

AU - Fabbietti, Paolo

AU - Testa, Roberto

AU - Boemi, Massimo

AU - Lattanzio, Fabrizia

AU - Olivieri, Fabiola

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤ 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up. In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.

AB - Leukocyte telomere length (LTL) shortening is found in a number of age-related diseases, including type 2 diabetes (T2DM). In this study its possible association with mortality was analyzed in a sample of 568 T2DM patients (mean age 65.9 ± 9 years), who were followed for a median of 10.2 years (interquartile range 2.2). A number of demographic, laboratory and clinical parameters determined at baseline were evaluated as mortality risk factors. LTL was measured by quantitative real-time PCR and reported as T/S (telomere-to-single copy gene ratio). Age, gender, creatinine, diabetes duration at baseline, and LTL were significantly different between T2DM patients who were dead and alive at follow-up. In the Cox regression analysis adjusted for the confounding variables, shorter LTL, older age, and longer disease duration significantly increased the risk of all-cause mortality (HR = 3.45, 95%CI 1.02-12.5, p = 0.004). Kaplan-Maier analysis also found a different cumulative mortality risk for patients having an LTL shorter than the median (T/S ≤ 0.04) and disease duration longer than the median (>10 years) (log-rank = 11.02, p = 0.011). Time-dependent mortality risk stratification showed that T2DM duration and LTL combined was a fairly good predictor of mortality over the first 76 months of follow-up. In conclusion, LTL combined with clinical parameters can provide additive prognostic information on mortality risk in T2DM patients.

KW - Aging

KW - Gerotarget

KW - Mortality

KW - Telomere shortening

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84982286100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982286100&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10615

DO - 10.18632/oncotarget.10615

M3 - Article

AN - SCOPUS:84982286100

VL - 7

SP - 50835

EP - 50844

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -